Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pharming Group's
Operating Income
for the
three
months ended in Mar. 2026 was $-5.3 Mil. Pharming Group's Interest Expense for the
three
months ended in Mar. 2026 was $-2.7 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pharming Group's Interest Coverage or its related term are showing as below:
PHAR'
s Interest Coverage Range Over the Past 10 Years
Min: 1.13 Med: 2.65 Max: 12.83
Current: 1.78
PHAR's Interest Coverage is ranked worse than 92.31% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs PHAR: 1.78
Pharming Group (NAS:PHAR) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pharming Group Interest Coverage Related Terms
Pharming Group Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pharming Group's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
PHAR vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Pharming Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pharming Group's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Pharming Group did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Pharming Group (PHAR) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharming Group and its competitors. Over the past decade, Pharming Group's Interest Coverage has ranged from 1.13 to 12.83. According to the industry distribution chart, Pharming Group ranks #348 out of 377 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Pharming Group's Interest Coverage too high?
Pharming Group's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 12.83. Based on the distribution chart, Pharming Group ranks #348 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #348 out of 377 companies for Interest Coverage. This places Pharming Group in the lower half of its industry. The industry median Interest Coverage is 106.07. Historically, Pharming Group's own Interest Coverage has ranged from 1.13 to 12.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharming Group and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.28, compared to a current price of $13.28 — trading 7% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pharming Group (PHAR), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.28 is trading 7% below its estimated GF Value™ of $14.28.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Interest Coverage: 0 (At Loss)
GF Value™: $14.28 vs. price of $13.28 (7% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score
Get the complete analysis for PHAR
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
